JP2010505897A - インフルエンザターゲット - Google Patents

インフルエンザターゲット Download PDF

Info

Publication number
JP2010505897A
JP2010505897A JP2009531778A JP2009531778A JP2010505897A JP 2010505897 A JP2010505897 A JP 2010505897A JP 2009531778 A JP2009531778 A JP 2009531778A JP 2009531778 A JP2009531778 A JP 2009531778A JP 2010505897 A JP2010505897 A JP 2010505897A
Authority
JP
Japan
Prior art keywords
kinase
influenza virus
gene
pharmaceutical composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009531778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505897A5 (cg-RX-API-DMAC7.html
Inventor
エフ. マイアー トーマス
カーラス アレキサンダー
マチュイ ニコラウス
マンツ ヤン−ダヴィド
ミュラー エルケ
ルーデル トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Original Assignee
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV filed Critical Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Publication of JP2010505897A publication Critical patent/JP2010505897A/ja
Publication of JP2010505897A5 publication Critical patent/JP2010505897A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009531778A 2006-10-11 2007-10-11 インフルエンザターゲット Pending JP2010505897A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85065106P 2006-10-11 2006-10-11
PCT/EP2007/008852 WO2008043561A2 (en) 2006-10-11 2007-10-11 Influenza targets

Publications (2)

Publication Number Publication Date
JP2010505897A true JP2010505897A (ja) 2010-02-25
JP2010505897A5 JP2010505897A5 (cg-RX-API-DMAC7.html) 2010-10-21

Family

ID=39203225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531778A Pending JP2010505897A (ja) 2006-10-11 2007-10-11 インフルエンザターゲット

Country Status (7)

Country Link
US (1) US20110150897A1 (cg-RX-API-DMAC7.html)
EP (1) EP2087110A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010505897A (cg-RX-API-DMAC7.html)
AU (1) AU2007306542B2 (cg-RX-API-DMAC7.html)
CA (1) CA2666185A1 (cg-RX-API-DMAC7.html)
SG (1) SG166778A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008043561A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549500A (ja) * 2020-11-13 2023-11-27 アルナイラム ファーマシューティカルズ, インコーポレイテッド 凝固第V因子(F5)iRNA組成物およびその使用方法

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EA200900741A1 (ru) 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2276455A2 (fr) * 2008-04-22 2011-01-26 Centre National de la Recherche Scientifique Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2405921A4 (en) * 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
WO2010111468A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
CN102459595A (zh) 2009-04-24 2012-05-16 普罗森那技术公司 用于治疗dmd的包含肌苷的寡核苷酸
WO2011071535A2 (en) * 2009-12-11 2011-06-16 Mount Sinai School Of Medicine Of New York University Compositions and methods for inhibiting human host cell factors required for influenza virus replication
JP2013515697A (ja) * 2009-12-23 2013-05-09 マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ インフルエンザ標的
EP2563921B1 (en) * 2010-04-30 2016-11-23 Cellectis Method for modulating double-strand break-induced homologous recombination
CN109112126B (zh) * 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
EP2633052B1 (en) * 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
EP2446883A1 (en) * 2010-10-30 2012-05-02 University College Cork-National University of Ireland, Cork Treatment of inflammation
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
WO2012122645A1 (en) * 2011-03-11 2012-09-20 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
US20140227289A1 (en) * 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013157215A1 (ja) * 2012-04-17 2013-10-24 国立大学法人山口大学 子宮体がん発症感受性の判定方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
BR112015022156A2 (pt) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
EP2853596A1 (en) 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Protein phosphatase inhibitor
US20160333346A1 (en) 2014-01-17 2016-11-17 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of inhibiting expression of beta-2gpi
JP6663149B2 (ja) * 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US20190071668A1 (en) * 2015-07-08 2019-03-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms
CA3005131A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of tuberous sclerosis complex
PT109454A (pt) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
MD3519572T2 (ro) 2016-09-29 2024-03-31 Biogen Ma Inc Compuși și procedee de reducere a expresiei Tau
TW201903149A (zh) 2017-05-31 2019-01-16 日商協和醱酵麒麟有限公司 抑制apcs之表現的核酸
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
CN111212909A (zh) * 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
EP3710587A1 (en) * 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
MY207352A (en) * 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
EP3689896A1 (en) * 2019-01-31 2020-08-05 Universität Heidelberg Grk2 modulating mirnas
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス,エルエルシー MRGX2の阻害薬である3-アミノ-4H-ベンゾ[e][1,2,4]チアジアジン1,1-ジオキシド誘導体
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
CN115397989A (zh) 2020-02-18 2022-11-25 阿尔尼拉姆医药品有限公司 载脂蛋白C3(APOC3)iRNA组合物及其使用方法
US20230190785A1 (en) * 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
WO2022072356A1 (en) * 2020-09-29 2022-04-07 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
GB202411150D0 (en) * 2024-07-30 2024-09-11 Res & Innovation Uk Therapeutic antisense oligomers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102461A2 (en) * 2005-03-22 2006-09-28 Massachusetts Institute Of Technology Influenza therapeutic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
US20030219895A1 (en) * 2002-05-22 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of CDC-like kinase 1 expression
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
DE10313636A1 (de) * 2003-03-26 2004-10-14 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102461A2 (en) * 2005-03-22 2006-09-28 Massachusetts Institute Of Technology Influenza therapeutic

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549500A (ja) * 2020-11-13 2023-11-27 アルナイラム ファーマシューティカルズ, インコーポレイテッド 凝固第V因子(F5)iRNA組成物およびその使用方法

Also Published As

Publication number Publication date
US20110150897A1 (en) 2011-06-23
WO2008043561A3 (en) 2008-10-02
SG166778A1 (en) 2010-12-29
AU2007306542A1 (en) 2008-04-17
WO2008043561A2 (en) 2008-04-17
CA2666185A1 (en) 2008-04-17
EP2087110A2 (en) 2009-08-12
AU2007306542B2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
AU2007306542B2 (en) Influenza targets
US20120282674A1 (en) Method for the preparation of an influenza virus
US8933046B2 (en) Influenza targets
Zhang et al. Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA
Keshavarz et al. miRNA-based strategy for modulation of influenza A virus infection
KR20050084607A (ko) 인플루엔자 치료제
Zhang et al. p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
Wu et al. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene
Shen et al. Altered viral replication and cell responses by inserting microRNA recognition element into PB1 in pandemic influenza A virus (H1N1) 2009
Wang et al. Critical role of microRNAs in host and influenza A (H1N1) virus interactions
Zavyalova et al. Aptamers to hemagglutinin: A novel tool for influenza virus recognition and neutralization
KR101839260B1 (ko) 조류인플루엔자 바이러스 miRNA 및 이의 식별, 검출과 응용
Jang et al. Molecular responses to the influenza A virus in chicken trachea-derived cells
Azhar et al. miRNAs in SARS-CoV-2 infection: an update
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
Hartawan et al. Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus
EP3154579A1 (en) New treatment against influenza virus
CN108113995A (zh) 微RNA hsa-mir-1-3p及其类似物的应用,和表达该微RNA载体的应用
Bamunuarachchi The Role of Tankyrase in Host Antiviral Responses to Influenza Virus Infection
CN103215345B (zh) 抑制流感病毒复制的宿主相关基因及其筛选方法和应用
Saengchoowong Enhanced propagation yield of influenza viruses for vaccine production through cellular microRNAs regulation
CN116531494A (zh) 一种CH25h在治疗H9N2亚型禽流感病毒感染药物中的应用
HK40004256A (en) Compositions and methods for providing a prognosis for influenza infection
Ward Host Modulators of the Death Response to Influenza A Infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100906

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130909